Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2014. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), or Connected Persons, in accordance with Disclosure and Transparency Rule (DTR) 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transactions and does not contain financial statements or performance metrics.
Material Changes
The filing reports changes in share interests arising from the reinvestment of dividends paid to shareholders on October 2, 2014. The transactions involved the purchase of Ordinary Shares at a price of 1,417.515 pence per share. No other material changes to the company's financial position or operations are disclosed in this text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is strictly administrative regarding director shareholdings.
Important Facts for Investors
- Transaction Date: Shares were purchased on October 2, 2014.
- Share Price: 1,417.515 pence per Ordinary Share.
- Transaction Type: Reinvestment of dividends paid on October 2, 2014.
- Directors and Connected Persons Involved:
- Sir Andrew Witty (Director): 4,258 Ordinary Shares.
- Lady C Witty (Connected person of Sir Andrew Witty): 2,045 Ordinary Shares.
- Mr I W Whyte (Connected person of Mrs V A Whyte): 268 Ordinary Shares.
- Signatory: Victoria Whyte, Company Secretary, signed on October 3, 2014.